Fe super(III)-Doped Two-Dimensional C sub(3)N sub(4) Nanofusiform: A New O sub(2)-Evolving and Mitochondria-Targeting Photodynamic Agent for MRI and Enhanced Antitumor Therapy

Local hypoxia in tumors, as well as the short lifetime and limited action region of super(1)O sub(2), are undesirable impediments for photodynamic therapy (PDT), leading to a greatly reduced effectiveness. To overcome these adversities, a mitochondria-targeting, H sub(2)O sub(2)-activatable, and O sub(2)-evolving PDT nanoplatform is developed based on Fe super(III)-doped two-dimensional C sub(3)N sub(4) nanofusiform for highly selective and efficient cancer treatment. The ultrahigh surface area of 2D nanosheets enhances the photosensitizer (PS) loading capacity and the doping of Fe super(III) leads to peroxidase mimetics with excellent catalytic performance towards H sub(2)O sub(2) in cancer cells to generate O sub(2). As such tumor hypoxia can be overcome and the PDT efficacy is improved, whilst at the same time endowing the PDT theranostic agent with an effective T sub(1)-weighted in vivo magnetic resonance imaging (MRI) ability. Conjugation with a mitochondria-targeting agent could further increase the sensitivity of cancer cells to super(1)O sub(2) by enhanced mitochondria dysfunction. In vitro and in vivo anticancer studies demonstrate an outstanding therapeutic effectiveness of the developed PDT agent, leading to almost complete destruction of mouse cervical tumor. This development offers an attractive theranostic agent for in vivo MRI and synergistic photodynamic therapy toward clinical applications. Highly selective and efficient cancer treatment can be achieved by overcoming photodynamic therapy (PDT) shortcomings, such as hypoxia, short lifetimes, and limited action region of super(1)O sub(2). A mitochondria-targeting, H sub(2)O sub(2)-activatable, and O sub(2)-evolving PDT nanoplatform is developed based on a Fe super(III)-doped, two-dimensional C sub(3)N sub(4) nanofusiform. This development offers an attractive theranostic agent for in vivo MRI and enhanced photodynamic therapy towards clinical applications.